Navigation Links
PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research
Date:4/28/2009

ANNAPOLIS, Md., April 28 /PRNewswire/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that results from a second Phase II study of SparVax(TM) were presented yesterday at the 12th Annual Conference on Vaccine Research, being held in Baltimore, MD, April 27-29, 2009. The conference is sponsored by the National Foundation of Infectious Diseases.

David P. Wright, President and Chief Executive Officer of PharmAthene commented, "We are very pleased to have had the opportunity to present these latest data for SparVax(TM) at Annual Conference on Vaccine Research. The study, which compared our vaccine to the currently licensed anthrax vaccine, BioThrax(R), provides further confirmation that SparVax(TM) is immunogenic and promotes good immunological recall following antigenic challenge. In addition, a lower incidence of injection site reactions observed with SparVax(TM) may suggest that it is better tolerated than BioThrax(R), a very important finding for this product candidate. Presentation of these data to attendees at this conference allows PharmAthene to continue to increase awareness of the progress we are making developing improved products using modern vaccine technologies to protect our Nation's citizens and military."

SparVax(TM) is a novel second generation recombinant protective antigen (rPA) anthrax vaccine that is being developed for pre and post exposure protection against anthrax infection.

SparVax(TM) Phase II Clinical Data

Results from a Phase II clinical trial of SparVax(TM) were presented during a poster session by Dr. Matthew Duchars, Chief Scientific Officer for PharmAthene.

The study was one of two Phase II trials evaluating different dose and dosing regimens of Sp
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. PharmAthene Announces $5.5 Million Public Equity Offering
2. PharmAthene To Host Year-End 2008 Earnings Conference Call and Webcast on Monday, March 30, 2009
3. PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting
4. PharmAthene Signs Agreement with Medison Pharma Ltd. to Commercialize and Distribute Biodefense Medical Countermeasures in Israel
5. Pharmathene Reports Third Quarter 2008 Financial and Operational Results
6. PharmAthene to Host Third Quarter 2008 Conference Call and Webcast on Thursday, November 13, 2008
7. PharmAthene to Present on Wednesday, November 12th at the 10th Annual Rodman & Renshaw Healthcare Conference
8. Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim(R)
9. PharmAthene and Panacea Biotec Ltd. Establish Strategic Alliance in Biodefense and Emerging Infectious Diseases
10. PharmAthene Awarded NIAID Contract For Up to $83.9 Million For Third Generation rPA Anthrax Vaccine Program
11. PharmAthene to Present Data for Protexia(R) and Valortim(R) at HHS PHEMCE Stakeholders Workshop 2008

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)... , REYKJAVIK, Iceland, November 24 /PRNews...DCGN ) today announced that it has received notice...company,s common stock will be,suspended as of Nov...h the,Securities and Exchange Commission, which wi...sdaq, unless the company files an appeal to the Na...
(Date:11/24/2009)... , REYKJAVIK, Iceland, November 24 /PRNews...DCGN ) today announced the approval of all of its,...or the District of Delaware,(the "Bankruptcy Court...r,relief under Chapter 11 of the United States Ban... The orders issued by the Bankruptcy Court allow t...
(Date:11/24/2009)... SHANGHAI, Nov. 24 /PRNewswire-Asia/ -- Shanghai...ug Administration (SFDA) has approved the,investig...sulin project,(Nodlin), an innovative insulin form...s Biolaxy to initiate its first phase I clinical s...stic of high blood glucose and poor,metabolism. Th...
(Date:11/24/2009)...Primary efficacy endpoint has been met for patient... cancer, , QUEBEC CITY, Nov. 24 /PRNewswire-F... TSX: AEZ) (the "Company"), a global biopharmaceut...logy, today announced positive efficacy data from ...e conjugate, AEZS-108 (formerly AN-152), in patien...
Breaking Biology Technology:deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 3deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3Biolaxy Secures IND Approval for Oral Insulin 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4
...I. - GE Medical Systems , has signed a clinical t...f the National Cancer Institute (NCI) for multi-si... an agent for positron emission tomography (PET), ... , ,FLT is a PET radiopharmaceutical used to imag...ence of cellular proliferation in tumors and other...
...I Nearly 60 people heard UW-Madison professor Raj...ent manager David Matthias stress the importance o...g of the Wisconsin Innovation Network (WIN) Founda... is the membership subsidiary of the Wisconsin Tec...fit science and technology advisor to the governor...
...en I meet a businessperson, one of the first ritua...d reach out for his or her card. In the business w...ice is even more ritualistic. , ,When I visited J... proper handling of the business card was so impor...meishi (pronounced "may-shee). I learned to take a...
Other Biology Technology:GE Medical Systems Signs Clinical Trial with National Cancer Institute 2WIN Northeast Wisconsin Chapter Launched for Regions Entrepreneurs 2Are You Your Business Card? 2Are You Your Business Card? 3
(Date:11/24/2009)... Medical Toxicology (ACMT) have signed an agreemen...l of Medical Toxicology (JMT), the official journ...reviously published by the University of Pennsylva... , an international, peer-reviewed journal, is ded...dical toxicology. The quarterly journal focuses o...
(Date:11/24/2009)...ter of debate. A high-profile study a few years ag...ir carbon from trees and leaves, evidence for a ve...ecosystems. , But new research from the Universi...ue. Algae provide a much richer diet for fish and ...d this week in the Proceedings of the National Ac...
(Date:11/23/2009)...ng evidence that the "synergistic" effect of early...lution and indoor endotoxin causes more harm to de...e. , Environmental health scientists at the Un...ve shown that children exposed to both high levels... during early life are six times more likely to ex...
Breaking Biology News(10 mins):Springer and the American College of Medical Toxicology to work together 2Fish food fight: Fish don't eat trees after all, says new study 2Fish food fight: Fish don't eat trees after all, says new study 3Exposure to both traffic, indoor pollutants puts some kids at higher risk for asthma later 2PJTV Invites Citizens to Engage in Virtual Health Care Forum on July 22 52026 1PJTV Invites Citizens to Engage in Virtual Health Care Forum on July 22 52026 2Top Obama administration officials to hold rural health community forum 52023 1Top Obama administration officials to hold rural health community forum 52023 2American Health Assistance Foundation 26 Asbury Methodist Village to Host Special Community Screenings and Discussion of HBO Series The Alzheimers Pr 52020 1American Health Assistance Foundation 26 Asbury Methodist Village to Host Special Community Screenings and Discussion of HBO Series The Alzheimers Pr 52020 2American Health Assistance Foundation 26 Asbury Methodist Village to Host Special Community Screenings and Discussion of HBO Series The Alzheimers Pr 52020 3American Health Assistance Foundation 26 Asbury Methodist Village to Host Special Community Screenings and Discussion of HBO Series The Alzheimers Pr 52020 4
...(March 17, 2008) -- According to researchers at th...in their responses to many sweet tastes than are a... molecules that humans experience as sweet do not ...ple, aspartame, a sweetener used by humans, does n...t flies respond positively to most sweeteners pref...
...Curators at one of the worlds most widely used bio...ource, or TAIR, have joined forces with the journa...ion dilemma. It is a first-of-its-kind partnership...portant genetics and other biological data about p...g the information highway and significantly increa...
... discoveries like the method for creating synthet...d or taken hostage by private corporations unless ...an expert from The Australian National University ...of Law takes a broad look at the current state of ...rty rights and biological inventions in his new bo...
Other Biology News:Like sweets? You're more like a fruit fly than you think... 2Controlling a sea of information 2Biotechnology needs 21st century patent system: Expert 2
Rat Serum Non-Sterile Trace-Hemolyzed from Pel-Freez Biologicals
...71-18 mutS and ES1301 mutS are mismatch repair min...ts repair of the newly synthesized unmethylated st...d making them helpful in such systems as the GeneE...th ES1301 and BMH 71-18 mutS are recA+, therefore ...
Human Granzyme B ELISPOT Kit from DiaPharma Group, Inc.
propidium iodide *1.0 mg/mL solution in water* from Molecular Probes (Invitrogen)
Biology Products: